Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) Director Daniel Janney sold 700 shares of the firm's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $275.00, for a total value of $192,500.00. Following the completion of the sale, the director directly owned 92,837 shares of the company's stock, valued at $25,530,175. The trade was a 0.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Daniel Janney also recently made the following trade(s):
- On Thursday, February 26th, Daniel Janney sold 7,741 shares of Krystal Biotech stock. The shares were sold at an average price of $275.63, for a total value of $2,133,651.83.
- On Tuesday, February 24th, Daniel Janney sold 13,825 shares of Krystal Biotech stock. The shares were sold at an average price of $268.34, for a total value of $3,709,800.50.
- On Tuesday, February 24th, Daniel Janney sold 37,895 shares of Krystal Biotech stock. The stock was sold at an average price of $266.88, for a total value of $10,113,417.60.
Krystal Biotech Stock Performance
Shares of KRYS stock opened at $273.29 on Friday. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $298.30. The firm has a market capitalization of $7.99 billion, a price-to-earnings ratio of 39.97 and a beta of 0.49. The stock's 50-day simple moving average is $268.29 and its 200-day simple moving average is $213.42.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Tuesday, February 17th. The company reported $1.70 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.08. The company had revenue of $107.11 million during the quarter, compared to analysts' expectations of $105.30 million. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. As a group, equities analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of KRYS. Seven Fleet Capital Management LP acquired a new position in Krystal Biotech in the fourth quarter valued at approximately $986,000. Pacer Advisors Inc. grew its stake in shares of Krystal Biotech by 182.0% during the 4th quarter. Pacer Advisors Inc. now owns 1,712 shares of the company's stock worth $422,000 after purchasing an additional 1,105 shares during the period. Vident Advisory LLC increased its holdings in shares of Krystal Biotech by 5.4% during the 4th quarter. Vident Advisory LLC now owns 1,494 shares of the company's stock valued at $368,000 after purchasing an additional 76 shares in the last quarter. EP Wealth Advisors LLC acquired a new position in shares of Krystal Biotech in the 4th quarter valued at $455,000. Finally, Empowered Funds LLC acquired a new position in shares of Krystal Biotech in the 4th quarter valued at $212,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
KRYS has been the topic of several research reports. Guggenheim upped their target price on Krystal Biotech from $224.00 to $284.00 and gave the company a "buy" rating in a research report on Wednesday. Bank of America increased their price objective on Krystal Biotech from $288.00 to $318.00 and gave the company a "buy" rating in a report on Thursday, January 22nd. TD Cowen reaffirmed a "buy" rating on shares of Krystal Biotech in a report on Friday, January 9th. HC Wainwright reiterated a "buy" rating and issued a $310.00 target price (up from $240.00) on shares of Krystal Biotech in a research report on Friday, January 9th. Finally, Jefferies Financial Group raised their price target on shares of Krystal Biotech from $310.00 to $371.00 and gave the stock a "buy" rating in a research report on Tuesday, February 17th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $326.25.
Read Our Latest Research Report on Krystal Biotech
About Krystal Biotech
(
Get Free Report)
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
